Pandemic Influenza – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Pandemic Influenza – Drugs In Development, 2024 report and make more profitable business decisions.
A flu pandemic is characterized by the worldwide spread of a novel flu A virus, and it occurs when this emerging virus has the capability to efficiently infect and transmit among humans, affecting a large population with limited immunity. Such pandemics are marked by the ability of the new influenza A virus to spread easily from person to person. The most recent instance of a flu pandemic took place in 2009 with the emergence of a novel influenza A (H1N1) virus.
The Pandemic Influenza drugs in development market research report provide comprehensive information on the therapeutics under development for Pandemic Influenza, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pandemic Influenza and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Pandemic Influenza | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 23 molecules, with 23 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Pandemic Influenza therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Pandemic Influenza pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Pandemic Influenza treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Arcturus Therapeutics Holdings IncBlueWillow Biologics Inc
CEL-SCI Corp
Centivax Inc
Cidara Therapeutics Inc
Cilian AG
Clover Biopharmaceuticals Ltd
Cocrystal Pharma Inc
EpiVax Inc
Etna Biotech Srl
Evrys Bio
Ilyang Pharmaceutical Co Ltd
Invivyd Inc
Longhorn Vaccines and Diagnostics LLC
Medigen Inc
Moderna Inc
Respana Therapeutics Inc
Sanofi
Seqirus Ltd
Shanghai Institute of Biological Products Co Ltd
SiVEC Biotechnologies LLC
Vaxxas Pty Ltd
Viramatix Sdn Bhd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Pandemic Influenza reports